**Correction to:** *Cell Death and Disease* (2014) **5,** e1291; doi:[10.1038/cddis.2014.251](/doifinder/10.1038/cddis.2014.251); published online 12 June 2014

Since the publication of this article the authors have noticed an error in [Figure 7c](#fig7){ref-type="fig"}. pS62DBcl-xL and pS62ABcl-xL are in the wrong order. The corrected figure is shown here.

The corrected article appears online together with this corrigendum. The authors would like to apologize for any inconvenience caused.

![Serine 62 phosphorylation of Bcl-xL occurring during prolonged mitotic arrest, promoted mitotic cell apoptosis. (**a**) Immunoblot analysis of S62 phosphorylation of Bcl-xL (pS62Bcl-xL) expression levels after Cdc20 depletion or paclitaxel treatment. MDA-MB-231 cells were transfected with either control or Cdc20 siRNA for 48 h or treated with paclitaxel for 12 h, harvested and the expression level of pS62Bcl-xL were finally evaluated by immunoblot analysis with S62-phospho-specific or total Bcl-xL antibodies. (**b**) Immunoblot analysis of Bcl-xL mutants. MDA-MB-231 cells were transfected with plasmids coding for wt Bcl-xL or S62(A or D)Bcl-xL mutants and analysed by immunoblotting 48 h later. (**c**) Apoptosis analysis of MDA-MB-231 cells after Bcl-xL or its S62 mutants (S62A- or S62D-Bcl-xL) overexpression, and treatment or not with paclitaxel and ABT-737, compared with control cells. MDA-MB-231 cells were transfected, respectively, with control plasmid (pCt), plasmids coding for Bcl-xL (pBcl-xL) or its S62(A or D) mutants (pS62(A or D)Bcl-xL). Cells were then treated with either DMSO or paclitaxel (70 nM), and finally stained with Annexin-V, and analysed by flow cytometry](cddis2014436f7){#fig7}
